Bronchiolar epithelium in idiopathic pulmonary fibrosis/usual interstitial fibrosis

Idiopathic Pulmonary Fibrosis

Volumn , Issue , 2003, Pages 631-664

  Chilosi, Marco ^a   Murer, Bruno ^b   Doglioni, Claudio ^c   Poletti, Venerino ^d   Semenzato, Gianpietro ^e  

^a UNIVERSITY OF VERONA   (Italy)

^b Mestre Hospital   (Italy)

^c Belluno Hospital   (Italy)

^d Forli Hospital   (Italy)

^e UNIVERSITY OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85057915147     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (195)

1. Mason RJ, Schwarz MI, Hunninghake GW, Musson RA. NHLBI Workshop Summary. Pharmacological therapy for idiopathic pulmonary fibrosis. Past, present, and future. Am J Respir Crit Care Med 1999; 160:1771–1777.
2. Selman M, King TE Jr., Pardo A. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med 2001; 134:136–151.
3. Kolb M, Margetts PJ, Anthony DC, Pitossi F, Gauldie J. Transient expression of IL-1beta induces acute lung injury and chronic repair leading to pulmonary fibrosis. J Clin Invest 2001; 107:1529–1536.
4. Sheppard D. Pulmonary fibrosis: a cellular overreaction or a failure of communication? J Clin Invest 2001; 107:1501–1502.
5. Keane MP, Belperio JA, Burdick MD, Lynch JP, Fishbein MC, Strieter RM. ENA-78 is an important angiogenic factor in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2001; 164:2239–2242.
6. Warburton D, Tefft D, Mailleux A, Bellusci S, Thiery JP, Zhao J, Buckley S, Shi W, Driscoll B. Do lung remodeling, repair, and regeneration recapitulate respiratory ontogeny? Am J Respir Crit Care Med 2001; 164:S59–S62.
7. Yamaguchi K, Mori M, Kawai A, Takasugi T, Oyamada Y, Koda E. Inhomogeneities of ventilation and the diffusing capacity to perfusion in various chronic lung diseases. Am J Respir Crit Care Med 1997; 156:86–93.
8. Liebow AA. Definition and classification of interstitial pneumonias in human pathology. Prog Respir Res 1975; 8:1–31.
9. American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS) (2000). Am J Respir Crit Care Med 161:646–664.
10. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. Am J Respir Crit Care Med 2002; 165:277–304.
11. Katzenstein AL, Myers JL. Idiopathic pulmonary fibrosis: clinical relevance of pathologic classification. Am J Respir Crit Care Med 1998; 157:1301–1315.
12. Travis WD, Matsui K, Moss J, Ferrans VJ. Idiopathic nonspecific interstitial pneumonia: prognostic significance of cellular and fibrosing patterns: survival comparison with usual interstitial pneumonia and desquamative interstitial pneumonia. Am J Surg Pathol 2000; 24:19–33.
13. Flaherty KR, Travis WD, Colby TV, Toews GB, Kazerooni EA, Gross BH, Jain A, Strawderman RL, Flint A, Lynch JP, Martinez FJ. Histopathologic variability in usual and nonspecific interstitial pneumonias. Am J Respir Crit Care Med 2001; 164:1722–1727.
14. Kuhn C, McDonald JA. The roles of the myofibroblast in idiopathic pulmonary fibrosis. Ultrastructural and immunohistochemical features of sites of active extracellular matrix synthesis. Am J Pathol 1991; 138:1257–1265.
15. Chilosi M, Poletti V, Murer B, Lestani M, Montagna L, Piccoli P, Pedron S, Semenzato G, Doglioni C, Menestrina F. The nature and significance of contractile cell hyperplasia in idiopathic pulmonary fibrosis. Submitted.
16. Kuhn C, Mason RJ. Immunolocalization of SPARC, tenascin, and thrombospondin in pulmonary fibrosis. Am J Pathol 1995; 147:1759–1769.
17. Paakko P, Kaarteenaho-Wiik R, Pollanen R, Soini Y. Tenascin mRNA expression at the foci of recent injury in usual interstitial pneumonia. Am J Respir Crit Care Med 2000; 161:967–972.
18. Jones PL, Jones FS. Tenascin-C in development and disease: gene regulation and cell function. Matrix Biol 2000; 19:581–596.
19. Chilosi M, Lestani M, Benedetti A, Montagna L, Pedron S, Scarpa A, Menestrina F, Hirohashi S, Pizzolo G, Semenzato G. Constitutive expression of tenascin in T-dependent zones of human lymphoid tissues. Am J Pathol 1993; 143:1348–1355.
20. Wallace WA, Howie SE, Lamb D, Salter DM. Tenascin immunoreactivity in cryptogenic fibrosing alveolitis. J Pathol 1995; 175:415–420.
21. Koch M, Wehrle-Haller B, Baumgartner S, Spring J, Brubacher D, Chiquet M. Epithelial synthesis of tenascin at tips of growing bronchi and graded accumulation in basement membrane and mesenchyme. Exp Cell Res 1991; 194:297–300.
22. Kaarteenaho-Wiik R, Tani T, Sormunen R, Soini Y, Virtanen I, Paakko P. Tenascin immunoreactivity as a prognostic marker in usual interstitial pneumonia. Am J Respir Crit Care Med 1996; 154:511–518.
23. Basset F, Ferrans VJ, Soler P, Takemura T, Fukuda Y, Crystal RG. Intraluminal fibrosis in interstitial lung disorders. Am J Pathol 1986; 122:443–461.
24. Myers JL, Katzenstein AL. Epithelial necrosis and alveolar collapse in the pathogenesis of usual interstitial pneumonia. Chest 1988; 94:1309–1311.
25. Lappi-Blanco E, Kaarteenaho-Wiik R, Soini Y, Risteli J, Paakko P. Intraluminal fibromyxoid lesions in bronchiolitis obliterans organizing pneumonia are highly capillarized. Hum Pathol 1999; 30:1192–1196.
26. Wallace WA, Roberts SN, Caldwell H, Thornton E, Greening AP, Lamb D, Howie SE. Circulating antibodies to lung protein(s) in patients with cryptogenic fibrosing alveolitis. Thorax 1994; 49:218–222.
27. Singh S, du Bois R. Autoantibodies in cryptogenic fibrosing alveolitis. Respir Res 2001; 2:61–63.
28. Kawanami O, Matsuda K, Yoneyama H, Ferrans VJ, Crystal RG. Endothelial fenestration of the alveolar capillaries in interstitial fibrotic lung diseases. Acta Pathol Jpn 1992; 42:177–184.
29. Kawanami O, Jiang HX, Mochimaru H, Yoneyama H, Kudoh S, Ohkuni H, Ooami H, Ferrans VJ. Alveolar fibrosis and capillary alteration in experimental pulmonary silicosis in rats. Am J Respir Crit Care Med 1995; 151:1946–1955.
30. Uhal BD, Joshi I, Hughes WF, Ramos C, Pardo A, Selman M. Alveolar epithelial cell death adjacent to underlying myofibroblasts in advanced fibrotic human lung. Am J Physiol 1998; 275:L1192–L1199.
31. Selman M, Ruiz V, Cabrera S, Segura L, Ramirez R, Barrios R, Pardo A. TIMP- 1, -2, -3, and -4 in idiopathic pulmonary fibrosis. A prevailing nondegradative lung microenvironment? Am J Physiol Lung Cell Mol Physiol 2000; 279:L562–L574.
32. Orr-Urtreger A, Givol D, Yayon A, Yarden Y, Lonai P. Developmental expression of two murine fibroblast growth factor receptors, flg and bek. Development 1991; 113:1419–1434.
33. Peters K, Werner S, Liao X, Wert S, Whitsett J, Williams L. Targeted expression of a dominant negative FGF receptor blocks branching morphogenesis and epithelial differentiation of the mouse lung. EMBO J 1994; 13:3296–3301.
34. Korfhagen TR, Whitsett JA. Transcriptional control in the developing lung. The Parker B. Francis lectureship. Chest 1997; 111(6 Suppl):83S–88S.
35. Inayama Y, Hook GE, Brody AR, Cameron GS, Jetten AM, Gilmore LB, Gray T, Nettesheim P. The differentiation potential of tracheal basal cells. Lab Invest 1988; 58:706–717.
36. Baldwin F. Basal cells in human bronchial epithelium. Anat Rec. 1994; 238: 360–367.
37. Boers JE, Ambergen AW, Thunnissen FB. Number and proliferation of basal and parabasal cells in normal human airway epithelium. Am J Respir Crit Care Med 1998; 157:2000–2006.
38. Evans MJ, Van Winkle LS, Fanucchi MV, Plopper CG. Cellular and molecular characteristics of basal cells in airway epithelium. Exp Lung Res 2001; 27:401–415.
39. Purkis PE, Steel JB, Mackenzie IC, Nathrath WB, Leigh IM, Lane EB. Antibody markers of basal cells in complex epithelia. J Cell Sci 1990; 97:39–50.
40. Evans MJ, Moller PC. Biology of airway basal cells. Exp Lung Res 1991; 17: 513–531.
41. Hicks W Jr., Hall L III, Sigurdson L, Stewart C, Hard R, Winston J, Lwebuga-Mukasa J. Isolation and characterization of basal cells from human upper respiratory epithelium. Exp Cell Res 1997; 237:357–363.
42. Erjefalt JS, Sundler F, Persson CG. Epithelial barrier formation by airway basal cells. Thorax 1997; 52:213–217.
43. Evans MJ, Cox RA, Shami SG, Wilson B, Plopper CG. The role of basal cells in attachment of columnar cells to the basal lamina of the trachea. Am J Respir Cell Mol Biol 1989; 1:463–469.
44. Watt FM, Hogan BL. Out of Eden: stem cells and their niches. Science 2000; 287:1427–1430.
45. Nettesheim P, Jetten AM, Inayama Y, Brody AR, George MA, Gilmore LB, Gray T, Hook GE. Pathways of differentiation of airway epithelial cells. Environ Health Perspect 1990; 85:317–329.
46. 3. Lab Invest 1976; 35:246–257.
47. 2. Am J Pathol 1986; 123:126–133.
48. Reynolds SD, Giangreco A, Power JH, Stripp BR. Neuroepithelial bodies of pulmonary airways serve as a reservoir of progenitor cells capable of epithelial regeneration. Am J Pathol 2000; 156:269–278.
49. Potten CS, Loeffler M. Stem cells: attributes, cycles, spirals, pitfalls and uncertainties. Lessons for and from the crypt. Development 1990; 110:1001–1020.
50. Slack JM. Stem cells in epithelial tissues. Science 2000; 287:1431–1433.
51. Chilosi M, Doglioni C. Constitutive p63 expression in airway basal cells. A molecular target in diffuse lung diseases. Sarcoidosis Vasc Diffuse Lung Dis 2001; 18:23–26.
52. Yang A, Kaghad M, Wang Y, Gillett E, Fleming MD, Dotsch V, Andrews NC, Caput D, McKeon F. p63, A p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol Cell 1998; 2:305–316.
53. Yang A, Schweitzer R, Sun D, Kaghad M, Walker N, Bronson RT, Tabin C, Sharpe A, Caput D, Crum C, McKeon F. p63 Is essential for regenerative proliferation in limb, craniofacial and epithelial development. Nature 1999; 398:714–718.
54. Pellegrini G, Dellambra E, Golisano O, Martinelli E, Fantozzi I, Bondanza S, Ponzin D, McKeon F, De Luca M. p63 Identifies keratinocyte stem cells. Proc Natl Acad Sci USA 2001; 98:3156–3161.
55. Signoretti S, Waltregny D, Dilks J, Isaac B, Lin D, Garraway L, Yang A, Montironi R, McKeon F, Loda M. p63 Is a prostate basal cell marker and is required for prostate development. Am J Pathol 2000; 157:1769–1775.
56. Mills AA, Zheng B, Wang XJ, Vogel H, Roop DR, Bradley A. p63 Is a p53 homologue required for limb and epidermal morphogenesis. Nature 1999; 22;398(6729):708–713.
57. Yang A, McKeon F. p63 and p73: p53 mimics, menaces and more. Nat Rev Mol Cell Biol 2000; 1:199–207.
58. Levine AJ. p53, The cellular gatekeeper for growth and division. Cell 1997; 88: 323–331.
59. Dulic V, Kaufmann WK, Wilson SJ, Tlsty TD, Lees E, Harper JW, Elledge SJ, Reed SI. p53-Dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest. Cell 1994; 76:1013–1023.
60. Agarwal ML, Taylor WR, Chernov MV, Chernova OB, Stark GR. The p53 network. J Biol Chem 1998; 273:1–4.
61. Herr I, Debatin KM. Cellular stress response and apoptosis in cancer therapy. Blood 2001; 98:2603–2614.
62. Chen X. The p53 family: same response, different signals? Mol Med Today 1999; 5:387–392.
63. Arrowsmith CH. Structure and function in the p53 family. Cell Death Differ 1999; 6:1169–1173.
64. Osada M, Ohba M, Kawahara C, Ishioka C, Kanamaru R, Katoh I, Ikawa Y, Nimura Y, Nakagawara A, Obinata M, Ikawa S. Cloning and functional analysis of human p51, which structurally and functionally resembles p53. Nature Med 1998; 4:839–843.
65. Parsa R, Yang A, McKeon F, Green H. Association of p63 with proliferative potential in normal and neoplastic human keratinocytes. J Invest Dermatol 1999; 113:1099–1105.
66. Liefer KM, Koster MI, Wang XJ, Yang A, McKeon F, Roop DR. Downregulation of p63 is required for epidermal UV-B–induced apoptosis. Cancer Res 2000; 60:4016–4020.
67. Dohn M, Jiang J, Chen X. Receptor tyrosine kinase EphA2 is regulated by p53- family proteins and induces apoptosis. Oncogene 2001; 20:6503–6515.
68. Dohn M, Zhang S, Chen X. p63alpha and DeltaNp63alpha can induce cell cycle arrest and apoptosis and differentially regulate p53 target genes. Oncogene 2001; 20:3193–3205.
69. Jung MS, Yun J, Chae HD, Kim JM, Kim SC, Choi TS, Shin DY. p53 and its homologues, p63 and p73, induce a replicative senescence through inactivation of NF-Y transcription factor. Oncogene 2001; 20:5818–5825.
70. Nishi H, Senoo M, Nishi KH, Murphy B, Rikiyama T, Matsumura Y, Habu S, Johnson AC. p53 Homologue p63 represses epidermal growth factor receptor expression. J Biol Chem 2001; 276:41717–41724.
71. Hagiwara K, McMenamin MG, Miura K, Harris CC. Mutational analysis of the p63/p73L/p51/p40/CUSP/KET gene in human cancer cell lines using intronic primers. Cancer Res 1999; 59:4165–4169.
72. Nishi H, Isaka K, Sagawa Y, Usuda S, Fujito A, Ito H, Senoo M, Kato H, Takayama M. Mutation and transcription analyses of the p63 gene in cervical carcinoma. Int J Oncol 1999; 15:1149–1153.
73. Shimada A, Kato S, Enjo K, Osada M, Ikawa Y, Kohno K, Obinata M, Kanamaru R, Ikawa S, Ishioka C. The transcriptional activities of p53 and its homologue p51/p63: similarities and differences. Cancer Res 1999; 59:2781–2786.
74. Ratovitski EA, Patturajan M, Hibi K, Trink B, Yamaguchi K, Sidransky D. p53 Associates with and targets Delta Np63 into a protein degradation pathway. Proc Natl Acad Sci USA 2001; 98:1817–1822.
75. Hibi K, Trink B, Patturajan M, Westra WH, Caballero OL, Hill DE, Ratovitski EA, Jen J, Sidransky D. AIS is an oncogene amplified in squamous cell carcinoma. Proc Natl Acad Sci USA 2000; 97:5462–5467.
76. Crook T, Nicholls JM, Brooks L, O’Nions J, Allday MJ. High level expression of DN-p63: a mechanism for the inactivation of p53 in undifferentiated nasopharyngeal carcinoma (NPC)? Oncogene 2000; 19:3439–3444.
77. Hibi K, Nakayama H, Taguchi M, Kasai Y, Ito K, Akiyama S, Nakao A. AIS overexpression in advanced esophageal cancer. Clin Cancer Res 2001; 7:469–472.
78. Chilosi M, Poletti V, Murer B, Lestani M, Cancellieri A, Montagna L, Piccoli P, Cangi G, Semenzato G, Doglioni C. Abnormal re-epithelialization and lung remodeling in idiopathic pulmonary fibrosis: the role of p63/p40. Lab Invest 2002; 82:1335–1345.
79. Bui KC, Buckley S, Wu F, Uhal B, Joshi I, Liu J, Hussain M, Makhoul I, Warburton D. Induction of A- and D-type cyclins and cdc2 kinase activity during recovery from short-term hyperoxic lung injury. Am J Physiol 1995; 268:L625–L635.
80. Driscoll B, Buckley S, Bui KC, Anderson KD, Warburton D. Telomerase in alveolar epithelial development and repair. Am J Physiol Lung Cell Mol Physiol. 2000; 279:L1191–L1198.
81. Lwebuga-Mukasa JS. Matrix-driven pneumocyte differentiation. Am Rev Respir Dis 1991; 144:452–457.
82. Kotton DN, Ma BY, Cardoso WV, Sanderson EA, Summer RS, Williams MC, Fine A. Bone marrow-derived cells as progenitors of lung alveolar epithelium. Development 2001; 128:5181–5188.
83. Glickman JN, Yang A, Shahsafaei A, McKeon F, Odze RD. Expression of p53- related protein p63 in the gastrointestinal tract and in esophageal metaplastic and neoplastic disorders. Hum Pathol 2001; 32:1157–1165.
84. Kurita T, Cunha GR. Roles of p63 in differentiation of Mullerian duct epithelial cells. Ann NY Acad Sci 2001; 948:9–12.
85. Westcott JL, Cole SR. Traction bronchiectasis in end-stage pulmonary fibrosis. Radiology 1986; 161:665–669.
86. Johkoh T, Muller NL, Ichikado K, Yoshida S, Honda O, Mihara N, Higashi M, Tomiyama N, Nakamura H, Nagareda T. Respiratory change in size of honeycombing: inspiratory and expiratory spiral volumetric CT analysis of 97 cases. J Comput Assist Tomogr 1999; 23:174–180.
87. Hironaka M, Fukayama M. Pulmonary fibrosis and lung carcinoma: a comparative study of metaplastic epithelia in honeycombed areas of usual interstitial pneumonia with or without lung carcinoma. Pathol Int 1999; 49: 1060–1066.
88. Meyer EC, Liebow AA. Relationship of interstitial pneumonia honeycombing and atypical epithelial proliferation to cancer of the lung. Cancer 1965; 18:322–351.
89. Auerbach O, Hammond EC, Garfinkel L. Changes in bronchial epithelium in relation to cigarette smoking, 1955–1960 vs. 1970–1977. N Engl J Med 1979; 300:381–385.
90. Slack JM. Homoeotic transformations in man: implications for the mechanism of embryonic development and for the organization of epithelia. J Theoret Biol 1985; 114:463–490.
91. Nomura S, Kaminishi M, Sugiyama K, Oohara T, Esumi H. Clonal analysis of isolated intestinal metaplastic glands of stomach using X linked polymorphism. Gut 1998; 42:663–668.
92. Stockstill BL, Chang LY, Menache MG, Mellick PW, Mercer RR, Crapo JD. Bronchiolarized metaplasia and interstitial fibrosis in rat lungs chronically exposed to high ambient levels of ozone. Toxicol Appl Pharmacol 1995; 134: 251–263.
93. Jensen-Taubman SM, Steinberg SM, Linnoila RI. Bronchiolization of the alveoli in lung cancer: pathology, patterns of differentiation and oncogene expression. Int J Cancer 1998; 75:489–496.
94. Nettesheim P, Szakal AK. Morphogenesis of alveolar bronchiolization. Lab Invest 1972; 26:210–219.
95. Dupuit F, Gaillard D, Hinnrasky J, Mongodin E, de Bentzmann S, Copreni E, Puchelle E. Differentiated and functional human airway epithelium regeneration in tracheal xenografts. Am J Physiol Lung Cell Mol Physiol 2000; 278:L165–L176.
96. Delplanque A, Coraux C, Tirouvanziam R, Khazaal I, Puchelle E, Ambros P, Gaillard D, Peault B. Epithelial stem cell-mediated development of the human respiratory mucosa in SCID mice. J Cell Sci 2000; 113:767–778.
97. Betsuyaku T, Fukuda Y, Parks WC, Shipley JM, Senior RM. Gelatinase B is required for alveolar bronchiolization after intratracheal bleomycin. Am J Pathol 2000; 157:525–535.
98. Kuwano K, Kunitake R, Kawasaki M, Nomoto Y, Hagimoto N, Nakanishi Y, Hara N. p21Waf1/Cip1/Sdi1 and p53 expression in association with DNA strand breaks in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1996; 154:477–483.
99. Guinee D Jr., Fleming M, Hayashi T, Woodward M, Zhang J, Walls J, Koss M, Ferrans, V, Travis W. Association of p53 and WAF1 expression with apoptosis in diffuse alveolar damage. Am J Pathol 1996; 149:531–538.
100. Maltzman W, Czyzyk L. UV irradiation stimulates levels of p53 cellular tumor antigen in nontransformed mouse cells. Mol Cell Biol 1984; 4:1689–1694.
101. Kaminski N, Allard JD, Pittet JF, Zuo F, Griffiths MJ, Morris D, Huang X, Sheppard D, Heller RA. Global analysis of gene expression in pulmonary fibrosis reveals distinct programs regulating lung inflammation and fibrosis. Proc Natl Acad Sci USA 2000; 97:1778–1783.
102. Hojo S, Fujita J, Yamadori I, Kamei T, Yoshinouchi T, Ohtsuki Y, Okada H, Bandoh S, Yamaji Y, Takahara J, Fukui T, Kinoshita M. Heterogeneous point mutations of the p53 gene in pulmonary fibrosis. Eur Respir J 1998; 12: 1404–1408.
103. Uematsu K, Yoshimura A, Gemma A, Mochimaru H, Hosoya Y, Kunugi S, Matsuda K, Seike M, Kurimoto F, Takenaka K, Koizumi K, Fukuda Y, Tanaka S, Chin K, Jablons DM, Kudoh S. Aberrations in the fragile histidine triad (FHIT) gene in idiopathic pulmonary fibrosis. Cancer Res 2001; 61:8527–8533.
104. Kawasaki H, Ogura T, Yokose T, Nagai K, Nishiwaki Y, Esumi H. p53 Gene alteration in atypical epithelial lesions and carcinoma in patients with idiopathic pulmonary fibrosis. Hum Pathol 2001; 32:1043–1049.
105. Vassilakis DA, Sourvinos G, Spandidos DA, Siafakas NM, Bouros D. Frequent genetic alterations at the microsatellite level in cytologic sputum samples of patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2000; 162:1115–1119.
106. Sozzi G, Pastorino U, Moiraghi L, Tagliabue E, Pezzella F, Ghirelli C, Tornielli S, Sard L, Huebner K, Pierotti MA, Croce CM, Pilotti S. Loss of FHIT function in lung cancer and preinvasive bronchial lesions. Cancer Res 1998; 58: 5032–5037.
107. Fraire AE, Greenberg SD. Carcinoma and diffuse interstitial fibrosis of lung. Cancer 1973; 31:1078–1086.
108. Turner-Warwick M, Lebowitz M, Burrows B, Johnson A. Cryptogenic fibrosing alveolitis and lung cancer. Thorax 1980; 35:496–499.
109. Panos RJ, Mortenson RL, Niccoli SA, King TE Jr. Clinical deterioration in patients with idiopathic pulmonary fibrosis: causes and assessment. Am J Med 1990; 88:396–404.
110. Mizushima Y, Kobayashi M. Clinical characteristics of synchronous multiple lung cancer associated with idiopathic pulmonary fibrosis. A review of Japanese cases. Chest 1995; 108:1272–1277.
111. Boers JE, ten Velde GP, Thunnissen FB. P53 in squamous metaplasia: a marker for risk of respiratory tract carcinoma. Am J Respir Crit Care Med 1996; 153:411–416.
112. Okudela K, Ito T, Mitsui H, Hayashi H, Udaka N, Kanisawa M, Kitamura H. The role of p53 in bleomycin-induced DNA damage in the lung. A comparative study with the small intestine. Am J Pathol 1999; 155:1341–1351.
113. Kunitake R, Kuwano K, Miyazaki H, Kawasaki M, Hagimoto N, Fujita M, Kaneko Y, Hara N. Expression of p53, p21 (Waf1/Cip1/Sdi1) and Fas antigen in collagen vascular and granulomatous lung diseases. Eur Respir J 1998; 12: 920–925.
114. Kuwano K, Hagimoto N, Nomoto Y, Kawasaki M, Kunitake R, Fujita M, Miyazaki H, Hara N. p53 and p21 (Waf1/Cip1) mRNA expression associated with DNA damage and repair in acute immune complex alveolitis in mice. Lab Invest 1997; 76:161–169.
115. Kawasaki H, Nagai K, Yokose T, Yoshida J, Nishimura M, Takahashi K, Suzuki K, Kakinuma R, Nishiwaki Y. Clinicopathological characteristics of surgically resected lung cancer associated with idiopathic pulmonary fibrosis. J Surg Oncol 2001; 76:53–57.
116. Adamson IY, Young L, King GM. Reciprocal epithelial: fibroblast interactions in the control of fetal and adult rat lung cells in culture. Exp Lung Res 1991; 17:821–835.
117. Weaver M, Dunn NR, Hogan BL. Bmp4 and Fgf10 play opposing roles during lung bud morphogenesis. Development 2000; 127:2695–2704.
118. Sakiyama J, Yokouchi Y, Kuroiwa A. Coordinated expression of Hoxb genes and signaling molecules during development of the chick respiratory tract. Dev Biol 2000; 227:12–27.
119. Cardoso WV. Molecular regulation of lung development. Annu Rev Physiol 2001; 63:471–494.
120. Shannon JM, Nielsen LD, Gebb SA, Randell SH. Mesenchyme specifies epithelial differentiation in reciprocal recombinants of embryonic lung and trachea. Dev Dyn 1998; 212:482–494.
121. Min H, Danilenko DM, Scully SA, Bolon B, Ring BD, Tarpley JE, DeRose M, Simonet WS. Fgf-10 is required for both limb and lung development and exhibits striking functional similarity to Drosophila branchless. Genes Dev 1998; 12: 3156–3161.
122. Mailleux AA, Tefft D, Ndiaye D, Itoh N, Thiery JP, Warburton D, Bellusci S. Evidence that SPROUTY2 functions as an inhibitor of mouse embryonic lung growth and morphogenesis. Mech Dev 2001; 102:81–94.
123. Cardoso WV. Transcription factors and pattern formation in the developing lung. Am J Physiol 1995; 269:L429–L442.
124. Minoo P, King RJ. Epithelial-mesenchymal interactions in lung development. Annu Rev Physiol 1994; 56:13–45.
125. Minoo P, Hamdan H, Bu D, Warburton D, Stepanik P, deLemos R. TTF-1 regulates lung epithelial morphogenesis. Dev Biol 1995; 172:694–698.
126. Minoo P, Su G, Drum H, Bringas P, Kimura S. Defects in tracheoesophageal and lung morphogenesis in Nkx2.1(-/-) mouse embryos. Dev Biol 1999; 209: 60–71.
127. Muraoka RS, Bushdid PB, Brantley DM, Yull FE, Kerr LD. Mesenchymal expression of nuclear factor-kappaB inhibits epithelial growth and branching in the embryonic chick lung. Dev Biol 2000; 225:322–338.
128. Sekine K, Ohuchi H, Fujiwara M, Yamasaki M, Yoshizawa T, Sato T, Yagishita N, Matsui D, Koga Y, Itoh N, Kato S. Fgf10 is essential for limb and lung formation. Nat Genet 1999; 21(1):138–141.
129. Kawakami Y, Capdevila J, Buscher D, Itoh T, Rodriguez Esteban C, Izpisua Belmonte JC. WNT signals control FGF-dependent limb initiation and AER induction in the chick embryo. Cell 2001; 104:891–900.
130. El-Hariry I, Pignatelli M, Lemoine NR. FGF-1 and FGF-2 regulate the expression of E-cadherin and catenins in pancreatic adenocarcinoma. Int J Cancer 2001; 94:652–661.
131. Manley NR. Thymus organogenesis and molecular mechanisms of thymic epithelial cell differentiation. Semin Immunol 2000; 12:421–428.
132. Chilosi M, Brighenti A, Zamò A, Montagna L, Piccoli P, Pedron S, Lestani M, Inghirami G, Doglioni C, Menestrina F. Constitutive expression of Delta N p63 alpha isoform in human thymus and thymic epithelial tumours. Virchows Arch 2003; July 8 (Epub ahead of print).
133. Chilosi M, Poletti V, Zamò A, Lestani M, Montagna L, Piccoli P, Pedron S, Bertaso M, Scarpa A, Murer B, Cancellieri A, Maestro R, Semenzato G, Doglioni C. Aberrant wnt/beta-catenin pathway activation in idiopathic pulmonary fibrosis. Am J Pathol 2003; 162:1495–1502.
134. Rimm DL, Caca K, Hu G, Harrison FB, Fearon ER. Frequent nuclear/cytoplasmic localization of beta-catenin without exon 3 mutations in malignant melanoma. Am J Pathol 1999; 154:325–329.
135. Brabletz T, Herrmann K, Jung A, Faller G, Kirchner T. Expression of nuclear beta-catenin and c-myc is correlated with tumor size but not with proliferative activity of colorectal adenomas. Am J Pathol 2000; 156:865–870.
136. Inomata M, Ochiai A, Akimoto S, Kitano S, Hirohashi S. Alteration of β-catenin expression in colonic epithelial cells of familial adenomatous polyposis patients. Cancer Res 1996; 56:2213–2217.
137. Hao XP, Pretlow TG, Rao JS, Pretlow TP. Beta-catenin expression is altered in human colonic aberrant crypt foci. Cancer Res 2001; 61:8085–8088.
138. Takayama T, Shiozaki H, Doki Y, Oka H, Inoue M, Yamamoto M, Tamura S, Shibamoto S, Ito F, Monden M. Aberrant expression and phosphorylation of β-catenin in human colorectal cancer. Br J Cancer 1998; 77:605–613.
139. Saito T, Oda Y, Kawaguchi Ki K, Tanaka K, Matsuda S, Tamiya S, Iwamoto Y, Tsuneyoshi M. Possible association between higher beta-catenin mRNA expression and mutated beta-catenin in sporadic desmoid tumors: real-time semiquantitative assay by TaqMan polymerase chain reaction. Lab Invest 2002; 82:97–103.
140. Keerthisingam CB, Jenkins RG, Harrison NK, Hernandez-Rodriguez NA, Booth H, Laurent GJ, Hart SL, Foster ML, McAnulty RJ. Cyclooxygenase-2 deficiency results in a loss of the anti-proliferative response to transforming growth factor-beta in human fibrotic lung fibroblasts and promotes bleomycininduced pulmonary fibrosis in mice. Am J Pathol. 2001; 158:1411–1422.
141. Poon R, Smits R, Li C, Jagmohan-Changur S, Kong M, Cheon S, Yu C, Fodde R, Alman BA. Cyclooxygenase-two (COX-2) modulates proliferation in aggressive fibromatosis (desmoid tumor). Oncogene 2001; 20:451–460.
142. Tebar M, Destree O, de Vree WJ, Ten Have-Opbroek AA. Expression of Tcf/Lef and sFrp and localization of beta-catenin in the developing mouse lung. Mech Dev 2001; 109:437–440.
143. Nusse R, Varmus HE. Wnt genes. Cell 1992; 69:1073–1087.
144. Hobmayer B, Rentzsch F, Kuhn K, Happel CM, von Laue CC, Snyder P, Rothbacher U, Holstein TW. WNT signalling molecules act in axis formation in the diploblastic metazoan Hydra. Nature 2000; 407:186–189.
145. Cadigan KM, Nusse R. Wnt signaling: a common theme in animal development. Genes Dev 1997; 11:3286–3305.
146. Kikuchi A Regulation of beta-catenin signaling in the Wnt pathway. Biochem Biophys Res Commun 2000; 268:243–248.
147. Oyama T, Kanai Y, Ochiai A, Akimoto S, Oda T, Yanagihara K, Nagafuchi A, Tsukita S, Shibamoto S, Ito F. A truncated beta-catenin disrupts the interaction between E-cadherin and alpha-catenin: a cause of loss of intercellular adhesiveness in human cancer cell lines. Cancer Res 1994; 54: 6282–6287.
148. Takeichi M. Cadherin cell adhesion receptors as a morphogenetic regulator. Science 1991; 251:1451–1455.
149. He TC, Sparks AB, Rago C, Hermeking H, Zawel L, da Costa LT, Morin PJ, Vogelstein B, Kinzler KW. Identification of c-MYC as a target of the APC pathway. Science 1998; 281:1509–1512.
150. Mann B, Gelos M, Siedow A, Hanski ML, Gratchev A, Ilyas M, Bodmer WF, Moyer MP, Riecken EO, Buhr HJ, Hanski C. Target genes of beta-catenin-T cell-factor/lymphoid-enhancer-factor signaling in human colorectal carcinomas. Proc Natl Acad Sci USA 1999; 96:1603–1608.
151. Tetsu O, McCormick F. Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 1999; 398:422–426.
152. Miller JR, Hocking AM, Brown JD, Moon RT. Mechanism and function of signal transduction by the Wnt/beta-catenin and Wnt/Ca2+ pathways. Oncogene 1999; 18:7860–7872.
153. Howe LR, Crawford HC, Subbaramaiah K, Hassell JA, Dannenberg AJ, Brown AM. PEA3 is up-regulated in response to Wnt1 and activates the expression of cyclooxygenase-2. J Biol Chem 2001; 276:20108–20115.
154. Crawford HC, Fingleton BM, Rudolph-Owen LA, Goss KJ, Rubinfeld B, Polakis P, Matrisian LM. The metalloproteinase matrilysin is a target of betacatenin transactivation in intestinal tumors. Oncogene 1999; 18:2883–2891.
155. Parks WC, Lopez-Boado YS, Wilson CL. Matrilysin in epithelial repair and defense. Chest 2001; 120(Suppl 1):36S–41S.
156. Dunsmore SE, Saarialho-Kere UK, Roby JD, Wilson CL, Matrisian LM, Welgus HG, Parks WC. Matrilysin expression and function in airway epithelium. J Clin Invest 1998; 102:1321–1331.
157. Ougolkov AV, Yamashita K, Mai M, Minamoto T. Oncogenic beta-catenin and MMP-7 (matrilysin) cosegregate in late-stage clinical colon cancer. Gastroenterology 2002; 122:60–71.
158. Betsuyaku T, Fukuda Y, Parks WC, Shipley JM, Senior RM. Gelatinase B is required for alveolar bronchiolization after intratracheal bleomycin. Am J Pathol 2000; 157:525–535.
159. Alman BA, Li C, Pajerski ME, Diaz-Cano S, Wolfe HJ. Increased beta-catenin protein and somatic APC mutations in sporadic aggressive fibromatoses (desmoid tumors). Am J Pathol 1997; 151:329–334.
160. Morin PJ, Sparks AB, Korinek V, Barker N, Clevers H, Vogelstein B, Kinzler KW. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science 1997; 275:1787–1790.
161. Rubinfeld B, Robbins P, El-Gamil M, Albert I, Porfiri E, Polakis P. Stabilization of beta-catenin by genetic defects in melanoma cell lines. Science 1997; 275: 1790–1792.
162. Korinek V, Barker N, Morin PJ, van Wichen D, de Weger R, Kinzler KW, Vogelstein B, Clevers H. Constitutive transcriptional activation by a betacatenin- Tcf complex in APC-/- colon carcinoma. Science 1997; 275:1784–1787.
163. Gat U, DasGupta R, Degenstein L, Fuchs E. De Novo hair follicle morphogenesis and hair tumors in mice expressing a truncated beta-catenin in skin. Cell 1998; 95:605–614.
164. Sunaga N, Kohno T, Kolligs FT, Fearon ER, Saito R, Yokota J. Constitutive activation of the Wnt signaling pathway by CTNNB1 (beta-catenin) mutations in a subset of human lung adenocarcinoma. Genes Chromosomes Cancer 2001; 30:316–321.
165. Letamendia A, Labbe E, Attisano L. Transcriptional regulation by Smads: crosstalk between the TGF-beta and Wnt pathways. J Bone Joint Surg Am 2001; 83(Suppl 1):S31–S39.
166. Labbe E, Letamendia A, Attisano L. Association of Smads with lymphoid enhancer binding factor 1/T cell-specific factor mediates cooperative signaling by the transforming growth factor-beta and wnt pathways. Proc Natl Acad Sci USA 2000; 97:8358–8363.
167. Nishita M, Hashimoto MK, Ogata S, Laurent MN, Ueno N, Shibuya H, Cho KW. Interaction between Wnt and TGF-beta signalling pathways during formation of Spemann’s organizer. Nature 2000; 403:781–785.
168. Heldin CH, Miyazono K, ten Dijke P. TGF-beta signalling from cell membrane to nucleus through SMAD proteins. Nature 1997; 390:465–471.
169. Massague J. TGF-beta signal transduction. Annu Rev Biochem 1998; 67: 753–791.
170. Pittet JF, Griffiths MJ, Geiser T, Kaminski N, Dalton SL, Huang X, Brown LA, Gotwals PJ, Koteliansky VE, Matthay MA, Sheppard D. TGF-beta is a critical mediator of acute lung injury. J Clin Invest 2001; 107:1537–1544.
171. Sime PJ, Xing Z, Graham FL, Csaky KG, Gauldie J. Adenovector-mediated gene transfer of active transforming growth factor-beta1 induces prolonged severe fibrosis in rat lung. J Clin Invest 1997; 100:768–776.
172. Khalil N, O’Connor RN, Unruh HW, Warren PW, Flanders KC, Kemp A, Bereznay OH, Greenberg AH. Increased production and immunohistochemical localization of transforming growth factor-beta in idiopathic pulmonary fibrosis. Am J Respir Cell Mol Biol 1991; 5:155–162.
173. Khalil N, Parekh TV, O’Connor R, Antman N, Kepron W, Yehaulaeshet T, Xu YD, Gold LI. Regulation of the effects of TGF-beta 1 by activation of latent TGF-beta 1 and differential expression of TGF-beta receptors (T beta R-I and T beta R-II) in idiopathic pulmonary fibrosis. Thorax 2001; 56:907–915.
174. Khalil N, O’Connor RN, Flanders KC, Unruh H. TGF-beta 1, but not TGF-beta 2 or TGF-beta 3, is differentially present in epithelial cells of advanced pulmonary fibrosis: an immunohistochemical study. Am J Respir Cell Mol Biol 1996; 14:131–138.
175. Crawford HC, Fingleton B, Gustavson MD, Kurpios N, Wagenaar RA, Hassell JA, Matrisian LM. The PEA3 subfamily of Ets transcription factors synergizes with beta-catenin-LEF-1 to activate matrilysin transcription in intestinal tumors. Mol Cell Biol 2001; 21:1370–1383.
176. Wilborn J, Crofford LJ, Burdick MD, Kunkel SL, Strieter RM, Peters-Golden M. Cultured lung fibroblasts isolated from patients with idiopathic pulmonary fibrosis have a diminished capacity to synthesize prostaglandin E2 and to express cyclooxygenase-2. J Clin Invest 1995; 95:1861–1868.
177. Homma S, Nagaoka I, Abe H, Takahashi K, Seyama K, Nukiwa T, Kira S. Localization of platelet-derived growth factor and insulin-like growth factor I in the fibrotic lung. Am J Respir Crit Care Med 1995; 152:2084–2089.
178. Uh ST, Inoue Y, King TE Jr., Chan ED, Newman LS, Riches DW. Morphometric analysis of insulin-like growth factor-I localization in lung tissues of patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1998; 158:1626–1635.
179. Playford MP, Bicknell D, Bodmer WF, Macaulay VM. Insulin-like growth factor 1 regulates the location, stability, and transcriptional activity of beta-catenin. Proc Natl Acad Sci USA 2000; 97:12103–12108.
180. Andre F, Rigot V, Thimonier J, Montixi C, Parat F, Pommier G, Marvaldi J, Luis J. Integrins and E-cadherin cooperate with IGF-I to induce migration of epithelial colonic cells. Int J Cancer 1999; 83:497–505.
181. Calvo R, West J, Franklin W, Erickson P, Bemis L, Li E, Helfrich B, Bunn P, Roche J, Brambilla E, Rosell R, Gemmill RM, Drabkin HA. Altered HOX and WNT7A expression in human lung cancer. Proc Natl Acad Sci USA 2000; 97:12776–12781.
182. Damalas A, Ben-Ze’ev A, Simcha I, Shtutman M, Leal JF, Zhurinsky J, Geiger B, Oren M. Excess beta-catenin promotes accumulation of transcriptionally active p53. EMBO J 1999; 18:3054–3063.
183. Sadot E, Geiger B, Oren M, Ben-Ze’ev A. Down-regulation of beta-catenin by activated p53. Mol Cell Biol 2001; 21:6768–6781.
184. Wang J, Shou J, Chen X. Dickkopf-1, an inhibitor of the Wnt signaling pathway, is induced by p53. Oncogene 2000; 19:1843–1848.
185. Kim K, Pang KM, Evans M, Hay ED. Overexpression of beta-catenin induces apoptosis independent of its transactivation function with LEF-1 or the involvement of major G1 cell cycle regulators. Mol Biol Cell 2000; 11: 3509–3523.
186. van Gijn ME, Snel F, Cleutjens JP, Smits JF, Blankesteijn WM. Overexpression of components of the Frizzled-Dishevelled cascade results in apoptotic cell death, mediated by beta-catenin. Exp Cell Res 2001; 265:46–53.
187. Ueda Y, Hijikata M, Takagi S, Takada R, Takada S, Chiba T, Shimotohno K. p73beta, a variant of p73, enhances Wnt/beta-catenin signaling in Saos-2 cells. Biochem Biophys Res Commun 2001; 283:327–333.
188. Adler KB, Low RB, Leslie KO, Mitchell J, Evans JN. Contractile cells in normal and fibrotic lung. Lab Invest 1989; 60:473–485.
189. Ohta K, Mortenson RL, Clark RA, Hirose N, King TE Jr. Immunohistochemical identification and characterization of smooth muscle-like cells in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1995; 152:1659–1665.
190. Corrin B. Pathology of the Lung. Churchill Livingstone, London, 2000, pp 248–249.
191. Sobue K, Hayashi K, Nishida W. Expressional regulation of smooth muscle cellspecific genes in association with phenotypic modulation. Mol Cell Biochem 1999; 190:105–118.
192. Sobue K, Sellers JR. Caldesmon, a novel regulatory protein in smooth muscle and nonmuscle actomyosin systems. J Biol Chem 1991; 266:12115–12118.
193. Miano JM, Cserjesi P, Ligon KL, Periasamy M, Olson EN. Smooth muscle myosin heavy chain exclusively marks the smooth muscle lineage during mouse embryogenesis. Circ Res 1994; 75:803–812.
194. Hayashi K, Saga H, Chimori Y, Kimura K, Yamanaka Y, Sobue K. Differentiated phenotype of smooth muscle cells depends on signaling pathways through insulin-like growth factors and phosphatidylinositol 3-kinase. J Biol Chem 1998; 273:28860–28867.
195. Johnson PR. Role of human airway smooth muscle in altered extracellular matrix production in asthma. Clin Exp Pharmacol Physiol 2001; 28:233–236.